NEURODERM
NeuroDerm is a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system (CNS) disorders that will make a clinically meaningful difference in patients’ lives. NeuroDerm’s technology enables new routes of administration for existing drugs that overcome their current deficiencies and achieve enhanced clinical efficacy.
NEURODERM
Industry:
Biotechnology Health Care Health Diagnostics Pharmaceutical
Founded:
2003-01-01
Address:
Rehovot, HaMerkaz, Israel
Country:
Israel
Website Url:
http://www.neuroderm.com
Total Employee:
101+
Status:
Active
Contact:
+972 8-946-2729
Total Funding:
18.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Google Universal Analytics
Similar Organizations
AZTherapies
AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
Recro Pharma
Recro Pharma is a pharmaceutical company developing non-opioid therapeutics for the treatment of pain.
Voyager Therapeutics
Voyager Therapeutics is a gene therapy company developing treatments for fatal and debilitating diseases of the central nervous system
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
The Elias Group
The Elias Group investment in Venture Round - NeuroDerm
Robert Taub
Robert Taub investment in Series A - NeuroDerm
Official Site Inspections
http://www.neuroderm.com Semrush global rank: 9.75 M Semrush visits lastest month: 113
- Host name: 104.22.54.102
- IP address: 104.22.54.102
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "NeuroDerm" on Search Engine
Our Company | Neuroderm
NeuroDerm is an agile, entrepreneurial R&D company, driving healthcare innovation and patient-centric solutions. By integrating the unique, complementary strengths and diverse capabilities of Pharma and MedTech under one roof, we create synergies and value in the space between existing drugs and innovative treatments and technologies.See details»
NeuroDerm, A Mitsubishi Tanabe Pharma Group …
About us. NeuroDerm is an agile and entrepreneurial R&D company, driving healthcare innovation and patient-centric solutions through Pharma & MedTech integration.See details»
NeuroDerm - Crunchbase Company Profile & Funding
Company Type For Profit. Phone Number +972 8-946-2729. NeuroDerm is a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system (CNS) disorders that will make a clinically meaningful difference in patients’ lives.See details»
Mitsubishi Tanabe buys up NeuroDerm in $1.1B deal
Jul 24, 2017 Mitsubishi Tanabe is to spend $1.1 billion on Parkinson’s disease biotech NeuroDerm as it looks to boost its U.S. presence and CNS pipeline. The deal comes several months after the Japanese...See details»
NeuroDerm - Drug-device Combination Solutions for Central …
NeuroDerm Overview. NeuroDerm specializes in integrating proprietary pharmaceutical formulations, state-of-the-art delivery system, and digital health solutions with the aim of reducing disease burden and improving the quality of life of patients and their families.See details»
Mitsubishi Tanabe to acquire NeuroDerm for $1.1B
Jul 24, 2017 NeuroDerm, a drug company focused on treatments for Parkinson’s disease (PD), has accepted a takeover bid from Mitsubishi Tanabe Pharma Corp. valued at roughly $1.1 billion. Announced Monday, the deal has the acquirer paying $39 per share of NeuroDerm, a 17% premium from the target’s July 21 closing stock price.See details»
Neuroderm stock up as FDA lifts hold on its ... - Fierce Pharma
May 10, 2015 The FDA lifted the clinical hold on Neuroderm's ($NDRM) subcutaneously delivered Parkinson's candidates, paving the way for more studies of the liquid formulations of levodopa and carbidopa in...See details»
Clinical Outlook on ND0612 in Parkinson’s Disease - Neurology live
Jan 11, 2023 NeuroDerm recently announced ND0612, a 24-hour/day subcutaneous infusion of liquid levodopa/carbidopa (LD/CD), met its primary end point in the phase 3 randomized, double-dummy BouNDless trial (NCT04006210) with improvement in ON time for patients with Parkinson Disease (PD).1 The treatment is designed with the purpose …See details»
ND0612 Subcutaneous Levodopa Delivery System Demonstrates …
Sep 17, 2021 Results from the open-label, nonrandomized, phase 2b BeyonND study (NCT02726386) demonstrated that treatment with ND0612 (Neuroderm), an investigational subcutaneous levodopa/carbidopa delivery system, increased good ON time while reducing OFF time and motor disability in patients with Parkinson disease (PD) and motor …See details»
NeuroDerm Ltd. - Drug pipelines, Patents, Clinical trials - Synapse
Mar 20, 2024 100-250. | NASDAQ: NDRM |. www.neuroderm.com. Last update 20 Mar 2024. Overview. Pipeline. Deal. Profit. Grant & Funding (NIH) Investment. Financing. Overview. Related. 3. Drugs associated with NeuroDerm Ltd. Target.See details»
News at NeuroDerm - The Official Board
The best decision-maker directory. NeuroDerm is owned by Mitsubishi Tanabe Pharma. See the recent changes among its 13 executives.See details»
NeuroDerm Ltd.: Drug pipelines, Patents, Clinical trials - Synapse
Originator Org. Mitsubishi Tanabe Pharma Corp. Active Indication - Inactive Indication. Attention Deficit Disorder With Hyperactivity. Drug Highest Phase Discontinued. First Approval Ctry. / Loc. First Approval Date - Target. DRDs. Mechanism. DRDs agonists. Active Org. - Originator Org.See details»
NeuroDerm - Funding, Financials, Valuation & Investors
NeuroDerm is registered under the ticker NASDAQ:NDRM . Their stock opened with $10.00 in its Nov 14, 2014 IPO. NeuroDerm is funded by 2 investors. The Elias Group and Robert Taub are the most recent investors. Unlock for free.See details»
Full article: On demand therapy for Parkinson’s disease patients ...
Jun 30, 2021 Altmetric. Listen. Clinical Focus: Neurological and Psychiatric Disorders - Review. On demand therapy for Parkinson’s disease patients: Opportunities and choices. Robert A. Hauser. , Peter A. LeWitt. & Cynthia L. Comella. Pages 721-727 | Received 11 Mar 2021, Accepted 25 May 2021, Published online: 30 Jun 2021. Cite this article.See details»
NeuroDerm - Contacts, Employees, Board Members, Advisors
Organization. NeuroDerm. Connect to CRM. Save. Summary Financials People Technology Signals & News Similar Companies. Highlights. Employee Profiles 6. Number of Board Member and Advisor Profiles 1. Contacts 55. About. NeuroDerm has 6 current employee profiles, including General Counsel and Chief Compliance Officer Hila Eitan.See details»
Home Realm Discovery
Sign in with one of these accounts. Active Directory. Other organization. Other organizational account.See details»
Levodopa/carbidopa subcutaneous - NeuroDerm - AdisInsight
Mar 22, 2024 Institution access. Drug Profile. Levodopa/carbidopa subcutaneous - NeuroDerm. Alternative Names: Carbidopa/levodopa subcutaneous - NeuroDerm; ND-0612; ND-0612H; ND-0612L; ND-0680. Latest Information Update: 22 Mar 2024. Price : $50 * Buy Profile. Adis is an information provider. We do not sell or distribute actual drugs.See details»
Nicotine/opipramol - NeuroDerm - AdisInsight - Springer
NeuroDerm (a subsidiary of Mitsubishi Tanabe Pharma Corporation) was developing a fixed dose combination of nicotine and opipramol, designated as ND 0801, for.See details»
Here are our current job openings | Neuroderm
Didn’t find the job you were looking for? Feel free to send us your CV and we will keep you informed about new openings.See details»